- Home
- ADAP vs MRCC Comparison
ADAP vs MRCC Comparison
Compare ADAP & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- MRCC
- Stock Information
- Founded
- ADAP 2008
- MRCC 2011
- Country
- ADAP United Kingdom
- MRCC United States
- Employees
- ADAP N/A
- MRCC N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- ADAP Health Care
- MRCC Finance
- Exchange
- ADAP Nasdaq
- MRCC Nasdaq
- Market Cap
- ADAP 212.3M
- MRCC 174.8M
- IPO Year
- ADAP 2015
- MRCC 2012
- Fundamental
- Price
- ADAP $0.62
- MRCC $8.17
- Analyst Decision
- ADAP Strong Buy
- MRCC Strong Buy
- Analyst Count
- ADAP 4
- MRCC 1
- Target Price
- ADAP $2.79
- MRCC $9.00
- AVG Volume (30 Days)
- ADAP 2.3M
- MRCC 71.5K
- Earning Date
- ADAP 11-13-2024
- MRCC 11-12-2024
- Dividend Yield
- ADAP N/A
- MRCC 12.15%
- EPS Growth
- ADAP N/A
- MRCC 298.01
- EPS
- ADAP N/A
- MRCC 0.60
- Revenue
- ADAP $175,041,000.00
- MRCC $62,007,000.00
- Revenue This Year
- ADAP $204.91
- MRCC N/A
- Revenue Next Year
- ADAP N/A
- MRCC N/A
- P/E Ratio
- ADAP N/A
- MRCC $13.71
- Revenue Growth
- ADAP 146.27
- MRCC N/A
- 52 Week Low
- ADAP $0.43
- MRCC $6.77
- 52 Week High
- ADAP $2.05
- MRCC $8.74
- Technical
- Relative Strength Index (RSI)
- ADAP 37.29
- MRCC 42.19
- Support Level
- ADAP $0.57
- MRCC $8.20
- Resistance Level
- ADAP $0.61
- MRCC $8.66
- Average True Range (ATR)
- ADAP 0.04
- MRCC 0.19
- MACD
- ADAP -0.00
- MRCC -0.06
- Stochastic Oscillator
- ADAP 27.46
- MRCC 1.85
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.